Research programme: Streptococcus pneumoniae vaccine - Zymenex

Alternative Names:
ACE 720

Latest Information Update: 04 Feb 2011

Price :
*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator
ACE BioSciences

Class
Vaccines

Mechanism of Action
Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

New Molecular Entity
No

Highest Development Phases

Discontinued
Streptococcal infections

Most Recent Events

09 Nov 2009
ACE BioSciences has been acquired by Zymenex A/S

06 Mar 2008
Preclinical development is ongoing

10 May 2005Streptococcus pneumoniae vaccine is available for licensing worldwide (http://www.acebiosciences.com)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription